ASIA unversity:Item 310904400/16716
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 94286/110023 (86%)
造访人次 : 21710633      在线人数 : 460
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/16716


    题名: Association between copy number variation of complement component C4 and Graves' disease.
    作者: 萬磊;Wan, Lei
    贡献者: 生物科技學系
    日期: 2011-09
    上传时间: 2012-11-23 09:16:13 (UTC+0)
    摘要: Background: Gene copy number of complement component C4, which varies among individuals, may determine
    the intrinsic strength of the classical complement pathway. Presuming a major role of complement as an effecter
    in peptide-mediated inflammation and phagocytosis, we hypothesized that C4 genetic diversity may partially
    explain the development of Graves’ disease (GD) and the variation in its outcomes.
    Methods: A case-control study including 624 patients with GD and 160 healthy individuals were enrolled. CNV of
    C4 isotypes (C4A and C4B) genes were performed by quantitative real-time polymerase chain reaction analysis.
    Statistical comparison and identification of CNV of total C4, C4 isotypes (C4A and C4B) and C4 polymorphisms were
    estimated according to the occurrence of GD and its associated clinical features.
    Results: Individuals with 4, 2, and 2 copies of C4, C4A and C4B genes, especially those with A2B2 polymorphism
    may associate with the development of GD (p = 0.001, OR = 10.994, 95% CI: 6.277-19.255; p = 0.008, OR = 1.732,
    95% CI: 1.190-2.520; p = 2.420 × 10-5, OR = 2.621, 95% CI: 1.791-3.835; and p = 1.395 × 10-4, OR = 2.671, 95% CI:
    1.761-4.052, respectively). Although the distribution of copy number for total C4, C4 isotypes as well as C4
    polymorphisms did not associate with the occurrence of goiter, nodular hyperplasia, GO and myxedema, <2 copies
    of C4A may associate with high risk toward vitiligo in patients with GD (p = 0.001, OR = 5.579, 95% CI:
    1.659-18.763).
    Conclusions: These results may be further estimated for its clinical application on GD and the vitiligo in patients
    with GD.
    關聯: JOURNAL OF BIOMEDICAL SCIENCE
    显示于类别:[生物科技學系] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML326检视/开启


    在ASIAIR中所有的数据项都受到原著作权保护.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈